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Indications for coronary angioplasty have expanded to include 
patients with unstable acute ischemic syndromes, severe multives-
sel coronary artery disease and impaired left ventricular function. 
Several mechanical approaches have been developed as adjuncts 
to high risk coronary angioplasty to improve patient tolerance of 
coronary balloon occlusion and maintain hemodynamic stability 
in the event of complications. 
These percutaneous techniques include intraaortic balloon 
counterpulsation, anterograde transcatheter coronary perfusion, 
coronary sinus retroperfusion, cardiopulmonary bypass, 
Hemopump"" left ventricular assistance and partial left heart 
bypass. The intraaortic balloon pump provides hemodynamic 
support and ameliorates ischemia by decreasing myocardial work; 
it may be inserted for periprocedural complications or before 
angioplasty in patients with ischemia or hypotension. 
Anterograde distal coronary artery perfusion may be accom-
plished passively through an autoperfusion catheter or by active 
Since the introduction of coronary angioplasty in 1977 0), 
indications for and application of this method of treating 
symptomatic coronary artery disease have expanded dra-
matically. Initially used primarily in patients in relatively 
stable condition who had single proximal coronary stenosis 
and normal left ventricular function, coronary angioplasty is 
now performed in patients with unstable ischemic syn-
dromes, multivessel coronary disease and, sometimes se-
verely impaired left ventricular function, cardiogenic shock 
or acute myocardial infarction (2-5). As might be expected, 
coronary angioplasty performed under these latter circum-
stances carries a substantially higher risk of periprocedural 
complications and associated mortality and morbidity (3,6). 
Certain groups of patients are considered to be at prohib-
itively high risk for coronary angioplasty. Typically, these 
patients have markedly impaired left ventricular function, a 
single target vessel supplying a large area of viable myocar-
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pumping of oxygenated blood or fluorocarbons through the cen-
tral lumen of an angioplasty catheter. Synchronized coronary 
sinus retroperfusion produces pulsatile blood flow via the cardiac 
veins to the coronary bed distal to a stenosis. Both perfusion 
techniques limit development of ischemic chest pain and myocar-
dial dysfunction in patients undergoing prolonged balloon infla-
tions. Percutaneous cardiopulmonary bypass provides complete 
systemic hemodynamic support which is independent of intrinsic 
cardiac function or rhythm and has been employed prophylacti-
cally in very high risk patients before coronary angioplasty or 
emergently for abrupt closure. 
These and newer support devices, while associated with signif-
icant complications, may ultimately improve the safety of coro-
nary angioplasty and allow its application to those who would 
otherwise not be candidates for revascularization. 
(J Am Coll CardioI1991;17:770-80) 
dium, or both. While angioplasty is generally well tolerated 
in the low risk setting (7), transient coronary occlusion 
induced by balloon inflations in these high risk patients may 
impose an intolerable ischemic burden on marginally com-
pensated myocardium and lead to hemodynamic collapse. In 
the event of abrupt vessel closure, many patients would not 
be expected to survive the 130 to 150 min time delay often 
required for emergency surgical revascularization (8,9). 
However, some patients with medically refractory ischemia 
are deemed poor candidates for coronary bypass surgery 
because of markedly diminished left ventricular function, 
poor target vessels or noncardiac contraindications. Thus, 
percutaneous revascularization, despite its high risk, may be 
the only therapeutic option for these persons. 
Several pharmacologic and mechanical techniques have 
been developed to improve tolerance of transient coronary 
occlusion during coronary angioplasty and to maintain he-
modynamic stability in the event of complications such as 
abrupt vessel closure. These methods may also permit more 
prolonged balloon inflation times, often required to improve 
short-term success rates and "tack down" intimal disrup-
tions (10,10. Modest improvements in delaying the onset of 
angina and electrocardiographic (ECG) evidence of ischemia 
during balloon inflation have been reported with intravenous 
and intracoronary administration of nitroglycerin, propran-
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Table 1. Current Percutaneous Support Devices for High-Risk or Complicated Coronary Angioplasty 
Device Size (F) Advantages Disadvantages Applications 
Intraaortic balloon 10.5 t Myocardial oxygen demand. Requires a stable cardiac rhythm and Prophylactic placement in selected 
high-risk patients. counterpulsation Ease of placement in 90% of output. 
patients. 9% to 43% incidence of vascular Support before CABO with 
complicated PICA. Prolonged treatment duration complications. 
possible. 
Anterograde perfusion 4.5 Improved myocardial oxygen Large profile catheter. Prolonged balloon inflations expected. 
Placement before bypass surgery with 
abrupt closure. 
supply. Ischemia of side branches involving the 
Hemoperfusion or stenosis. 
fluosol perfusion possible. Removal of guide wire needed. 
Thrombosis risk. 
Coronary sinus 8.5 Maintains perfusion to branches Perfusion improvement documented Prolonged balloon inflations in high 
risk patients.lnvestigational. retroperfusion compromised by PICA. only in LAD distribution. 
No specialized PTCA catheter. Incomplete protection from ischemia. 
Complex apparatus and additional 
arterial and venous access. 
Cardiopulmonary 18-20 Independent of LV function or No improvement of coronary perfusion. Prophylactic placement in very high 
risk patients. support rhythm. 40% vascular complications. 
t Myocardial oxygen demand. 
Other devices 
Severe hemodynamic compromise 
after complicated PICA. 
Hemopump 21 Direct LV decompression. Requires arteriotomy and adequate Investigational 
Use up to 14 days possible. femoral artery size for placement. 
Independent of LV function or Arrhythmogenic LV cannula. 
rhythm. Potential for dislodgment from LV. 
Partial left heart 14-20 No oxygenator required. Requires large bore transseptal Investigational 
bypass May decompress LV. cannulation. 
CABO = coronary bypass surgery; LAD = left anterior descending artery; LV = left ventricle; PICA = percutaneous transluminal coronary angioplasty; 
t = decreased. 
0101 and calcium channel antagonists (12), but the response 
to pharmacologic agents in this setting is generally unpre-
dictable. Several innovative mechanical approaches have 
been advocated as adjuncts to high risk or complicated 
coronary angioplasty; their current advantages, limitations, 
and potential applications will be reviewed (Table I). 
Intraaortic Balloon Counterpulsation 
Introduced in 1968 (13) for the hemodynamic stabilization 
of patients with complicated myocardial infarction and car-
diogenic shock, intraaortic balloon counterpulsation has 
since been shown (14) to have symptomatic benefit in 
patients with unstable angina, postinfarction angina and 
refractory congestive heart failure. The technique has been 
reviewed in depth (14). Myocardial oxygen consumption is 
reduced by lO% to 20%, and there are conflicting reports 
(15,16) as to whether coronary blood flow is improved. 
Despite the paucity of controlled trials demonstrating the 
clinical efficacy of intraaortic balloon counterpUlsation, ex-
tensive anecdotal experience demonstrates its value in sta-
bilizing the patient's condition before or during coronary 
angioplasty (Table 2). 
Limitations and complications. The most important limi-
tation of supported angioplasty using the intraaortic balloon 
pump (17-23) is its modest augmentation of cardiac output 
and dependence on a stable cardiac rhythm. In the series of 
Alcan et al. (18), for example, only one of seven patients 
who presented in cardiac arrest survived, and mortality 
among patients with established cardiogenic shock was 94%. 
Similarly, Phillips (24) reported on seven patients in refrac-
tory cardiac arrest who did not respond to initial attempts at 
resuscitation using intraaortic balloon counterpulsation; all 
were subsequently resuscitated with percutaneous cardio-
pulmonary bypass. With advances in equipment design and 
operator experience, the initial complications noted with 
prototype balloon devices (25) have been reduced. Now, 
intraaortic balloon insertion is possible in >90% of patients, 
with failure usually due to ileofemoral atherosclerosis (14). 
Nevertheless, vascular complications still occur in 9% to 
43% of patients (14,26), and result from thrombosis, embo-
lization or bleeding at the site of vascular access. In the 
review by Alderman et al. (26), risk factors for limb ischemia 
were diabetes, peripheral vascular disease, and female gen-
der; 27% of patients required premature discontinuation of 
balloon counterpulsation, 15% underwent vascular surgical 
repair and 9% had evidence of persistent ischemia at hospital 
discharge. 
Indications during coronary angioplasty. Intra-aortic bal-
loon counterpulsation may be an effective supportive ad-
junct to coronary angioplasty in at least two situations. 
Prophylactic intraaortic balloon pump placement may be 
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Table 2. Use of Intraaortic Balloon Counterpulsation to Provide Hemodynamic Stabilization of Patients Before High Risk and After 
Complicated Coronary Angioplasty 
Reference 
(first author) n High Risk Feature Clinical Effects 
Before high-risk coronary angioplasty 
Szatmary (17) 16 
Alcan (18) 9 
Hypotension (SBP < 100) 
Poor LV function (EF < 40%) 
Unstable angina 
Cardiogenic shock (n = 2) 
Unstable angina (n = 7) 
Clinical stability leading to successful angioplasty 
in all patients 
Clinical stability leading to successful angioplasty 
in all patients 
Voudris (19) 27 Poor LV function (EF < 40%) (n = 24) 
Multivessel disease (n = 3) 
Successful angioplasty in all patients 
Kahn (20) 28 Poor LV function (EF < 30%) (n =17) Hemodynamic stability; no QWMI or death 
Single patent vessel or left main disease (n = II) 
Urgent placement after coronary angioplasty 
Alcan (18) 5 
Margolis (21) 
Murphy (22) 
Jones (23) 
Phillips (24) 
5 
32 
12 No IABP, 
8IABP 
7 
Abrupt closure (n = 3) 
Unsuccessful PTCA (n = 2) 
Abrupt closure 
Abrupt closure 
Complicated PTCA with 
ST segment elevations 
Cardiac arrest 
MI (n = 4) 
Failed PTCA (n = 3) 
Hemodynamic stabilization before CABG (4) 
Resolution of chest pain and ST segment 
elevation 
Improvement in hypotension; 
20% QWMI in IS patients with ST segment 
elevation 
No IABP-lOO% QWMI after CABG 
IABP-25% QWMI after CABG 
Ineffective in restoring stability 
EF = ejection fraction; IABP = intraaortic balloon counterpulsation; QWMI = Q wave myocardial infarction: SBP = systolic blood pressure; other 
abbreviations as in Table I. 
beneficial in high risk patients with hemodynamic instability, 
poor left ventricular function and an unstable coronary 
syndrome, especially when prolonged angioplasty balloon 
inflations may be anticipated. Intraaortic balloon counterpul-
sation may also provide a valuable bridge to anesthesia 
induction and cardiac surgery in patients in whom compli-
cations of coronary angioplasty develop. In the absence of 
intrinsic cardiac output and a stable rhythm, however, 
intraaortic balloon counterpulsation is of little hemodynamic 
benefit, and more advanced circulatory support devices may 
be required. 
Anterograde Coronary Perfusion 
With the demonstration that transient coronary occlusion 
is generally well tolerated in most low risk patients under-
going coronary angioplasty (7), early experimental methods 
designed to maintain distal coronary perfusion during bal-
loon inflation were not extended to clinical trials. Resur-
gence of interest in distal coronary perfusion occurred as a 
result of the increasing proportion of high risk patients 
undergoing coronary angioplasty and the trend toward pro-
longed inflation times in the setting of arterial dissection. 
Currently, distal anterograde coronary perfusion may be 
maintained during and after angioplasty by three methods: 
coronary autoperfusion and active transcatheter infusion of 
blood or oxygenated perfluorocarbons. 
Coronary Autoperfusion 
"Bailout" catheter. Autoperfusion catheters, designed to 
provide anterograde coronary perfusion driven by central 
aortic pressure, are available in three different designs. The 
reperjusion or "bailout" catheter restores distal coronary 
perfusion after failed or complicated coronary angioplasty, 
thereby permitting controlled surgical revascularization (27). 
Once the distal coronary guide wire and guiding catheter are 
removed, this 4.3F coronary infusion catheter with mUltiple 
proximal and distal sideholes provides up to 80 ml/min of 
passive blood flow across the coronary stenosis. Use of the 
reperfusion catheter in dogs during 90 min coronary occlu-
sion has shown nearly 70% of baseline coronary flow to the 
myocardium at risk and no demonstrable evidence of myo-
cardial infarction (28). In the nonrandomized series of 31 
patients in whom abrupt closure developed after coronary 
angioplasty, as reported by Sundram et al. (29), the bailout 
catheter was successfully placed before surgery in II (61 %) 
of 18. The rate of Q wave infarction was 9% in patients 
managed with the reperfusion catheter versus 75% in pa-
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Figure 1. Perfusion balloon catheter placed in the proximal right 
coronary artery of a patient with a large dissection and compromised 
flow after standard balloon angioplasty. Proximal contrast injection 
demonstrates perfusion through the balloon catheter into the distal 
right coronary artery. 
tients who received intraaortic balloon counterpulsation or 
no mechanical intervention. 
Perfusion balloon catheter. To provide anterograde coro-
nary perfusion during periods of prolonged coronary balloon 
inflation, a second method of coronary autoperfusion was 
developed (30-33). Consisting of a 4.5F catheter with a 
20 mm balloon and 10 proximal and four distal sideholes, a 
perfusion balloon catheter can be advanced across the 
stenosis and the central guide wire withdrawn to a position 
proximal to the sideholes. After balloon inflation and re-
moval of the guiding catheter from the coronary ostium, 
blood enters the proximal sideholes, flows through the 
central lumen and exits the catheter distal to the coronary 
stenosis (Fig. O. Flow rates are linearly proportional to 
proximal arterial perfusion pressure (33). In canine studies, 
myocardial perfusion in the region of coronary occlusion 
was maintained using the perfusion balloon catheter, in 
contrast to the five- to sevenfold reduction in regional 
coronary blood flow using standard balloon techniques (31). 
Prolonged balloon inflations-up to 90 min-have been 
achieved experimentally with only minor reductions in re-
gional coronary perfusion and no evidence of significant 
myocardial ischemia or infarction (28,32). Similarly, clinical 
studies (34) show that balloon inflations using the perfusion 
balloon catheter can be tolerated for approximately 15 min 
with little or no ischemic ECG changes, angina or enzymatic 
evidence of myocardial necrosis. This method of prolonged 
perfusion balloon angioplasty is being used more often in 
patients with arterial dissection after coronary angioplasty 
and in patients clinically or hemodynamically intolerant of 
standard balloon inflations. 
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Limitations. Application of both of these techniques of 
autoperfusion has been limited primarily by the relative 
stiffness of the autoperfusion catheter and its large, 0.064 in. 
(0.163 cm) deflated profile (35). Coronary lesions located at 
bend points or in tortuous, small or diffusely diseased 
vessels may not be readily accessible to passage of the 
autoperfusion catheter. Further, these devices may be inef-
fective in preventing ischemia in the distribution of side 
branches crossed by the stenosis or angioplasty balloon. 
Passive flow rates through the autoperfusion catheter, par-
ticularly in the setting of hypotension, may not be sufficient 
in all cases to completely prevent ischemia, and some degree 
of myocardial necrosis has been reported (32,33). Streptoki-
nase flushes through the catheter lumen may reduce, but do 
not prevent, the formation of thrombus due to low velocity 
flow. 
Transient coronary stenting. Recently, a 4F stainless 
steel mesh retrievable stent has been used to maintain 
coronary perfusion after abrupt vessel closure in humans 
(36). Although clinical information is limited, it has been 
used for periods of up to 90 min without clinical or ECG 
evidence of myocardial ischemia. Furthermore, in contrast 
to use of the perfusion balloon catheter, side branch perfu-
sion is not compromised during the period of temporary 
stenting. This innovative new method of temporary stenting 
awaits further clinical trials. The alternative of permanent 
endoluminal stents, emergently implanted in this setting, 
have in early studies reversed vessel closure and obviated 
the need for bypass surgery (37). 
Coronary Hemoperjusion 
Hemoperfusion during balloon occlusion. To overcome 
the technical limitations of coronary autoperfusion, such as 
large perfusion catheter profile and limited flow rates at low 
perfusion pressures, methods designed to pump blood 
through the central lumen of standard balloon angioplasty 
catheters have been developed. Various techniques of pro-
viding hemoperfusion during coronary balloon occlusion 
have been reported (38-40. After withdrawal from the renal 
vein or the side arm of an oversized arterial sheath, blood is 
heparinized and reinfused using hand injection (38), roller 
pump or angiographic power injector; the latter approach is 
most effective in providing adequate and reproducible flow 
rates (39). With the coronary guide wire removed, flow rates 
of up to 80 mllmin may be obtained; 20 to 35 mllmin of blood 
flow is feasible with the guide wire in place and appears to be 
sufficient to eliminate or markedly diminish angina and ECG 
evidence of ischemia during balloon inflations (38). Lehmann 
et at. (40) compared 60 s balloon inflations in 15 patients with 
and without coronary hemoperfusion; patients with hemo-
perfusion had significantly less chest pain and ST segment 
elevation during coronary occlusion. Similarly, echocardiog-
raphy performed during coronary angioplasty with coronary 
hemoperfusion showed normalization of transient regional 
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wall motion abnormalities induced by balloon inflation 
(42,43). 
Feasibility and safety. Initial concerns about the feasibil-
ity and safety of coronary hemoperfusion focused on ques-
tions of hemolysis, distal coronary thrombosis, and coronary 
trauma from the exiting high pressure jet; to date these 
complications have not been reported. The major limita-
tion of the hemoperfusion technique, similar to that of the 
autoperfusion catheter, is that blood flow to coronary side 
branches occluded by the inflated angioplasty balloon re-
mains impaired. This effect seems particularly common in 
diagonal branches of the left anterior descending artery, and 
may be ameliorated in some cases by repositioning of the 
angioplasty balloon. With adequate heparinization (15,000 to 
20,000 U) and possibly intermittent catheter flushes with 
streptokinase or urokinase, catheter thrombosis appears to 
be unlikely. 
Per fluorocarbon Coronary Perfusion 
Fluosol. Fluosol, a biologically inert perfluorocarbon 
emulsion with an oxygen-carrying capacity of 7 ml 02/dl at 
600 torr, was recently commercially approved as a distal 
coronary perfusate during coronary angioplasty. Potential 
advantages of f1uosol over blood include its low viscosity 
and the absence ofhemoloysis at high flow rates (44). Canine 
experiments (45) indicate that intravenous administration of 
f1uosol may limit reperfusion injury after 90 min of coronary 
occlusion by suppression of neutrophil chemotaxis and 
lysozyme release. In a pilot study, Clem an et al. (46) infused 
f1uosol in 20 patients undergoing left anterior descending 
artery angioplasty and demonstrated lack of regional wall 
motion abnormalities by echocardiography. In a small, ran-
domized trial (47) only modest reduction of ischemic indexes 
during angioplasty were noted. A recent multicenter, ran-
domized trial (44) of f1uosol intracoronary infusion in 245 
patients demonstrated intraprocedural improvement of re-
gional myocardial function and a decrease in the rate of ST 
segment elevation. 
Perftuorocarbon infusion versus hemoperfusion. Despite 
these beneficial effects of f1uosol, whether perfluorocarbon 
infusion represents an improvement over hemoperfusion is 
controversial. In experimental canine occlusion (42), distal 
coronary infusion of blood normalized left ventricular func-
tion, myocardial metabolism assessed by lactate extraction, 
and ECG ST segments. Fluosol, however, produced incom-
plete improvements in regional myocardial dysfunction and 
metabolism. Other studies (48) comparing f1uosol infusions 
with blood infusion indicate that autologous blood is proba-
bly the better perfusate. Thus, while f1uosol does provide 
some degree of myocardial protection during coronary an-
gioplasty, perfluorocarbon administration does not seem to 
offer an advantage over autologous blood for infusion during 
standard angioplasty. Further, the 30 to 60 min requisite 
preparation and oxygenation time may limit the clinical 
usefulness of f1uosol in this setting. 
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Coronary Sinus Retroperfusion 
Modern interest in the coronary sinus as an alternative 
conduit for myocardial perfusion originated with experimen-
tal studies during the 1940s (49). Arterialization of the 
coronary sinus was first performed in humans by Beck in 
1948, by the construction of a vein graft from the aorta to the 
coronary sinus. This procedure furnished some degree of 
myocardial protection from left anterior descending artery 
occlusion in dogs as well as relief of angina in selected 
patients with symptomatic coronary artery disease (49). 
Unfortunately, most patients eventually developed late myo-
cardial hemorrhage, edema and fibrosis and thrombosis of 
the venous drainage system. 
Synchronized coronary sinus retroperfusion. In 1976, ex-
perimental work by Meerbaum et al. (50) renewed interest in 
developing retroperfusion by way of the coronary sinus as 
therapy for acute ischemic syndromes. By delivering retro-
perfused blood in a pulsatile manner through a nonocclusive 
coronary sinus catheter during diastole, normal coronary 
venous drainage occurred during systole and the adverse 
effects of myocardial hemorrhage and edema did not occur. 
The technique of pressure-controlled intermittent coronary 
sinus occlusion was also investigated as a means of redis-
tributing coronary blood flow through coronary venous 
pressure gradients, but arterialization of the coronary sinus 
system was demonstrated to be clearly superior in limiting 
infarctsize in the canine model (51). Synchronized coronary 
sinus retroperfusion was improved with the development of 
an inflatable balloon-tipped coronary sinus perfusion cathe-
ter (52). This system, consisting of an 8.5F retroperfusion 
catheter introduced into the coronary sinus through the right 
or left internal jugular or left subclavian vein and advanced 
into the great cardiac vein (Fig. 2), has reduced experimental 
infarct size (52). Arterial blood obtained from the femoral 
artery is infused through the catheter during ventricular 
diastole; a 10 mm balloon located 1 cm from its tip inflates 
and deflates with pressurized carbon dioxide gas during each 
cardiac cycle, preventing escape ofretroperfused blood into 
the right atrium; flow rates of up to 250 mllmin may be 
obtained (53). 
Application in coronary angioplasty. Since favorable clin-
ical results in patients with unstable angina (54) have been 
reported, use of synchronized retroperfusion has been ap-
plied as an adjunct to coronary angioplasty (55,56). In 28 
patients undergoing left anterior descending artery angio-
plasty, retroperfusion was successful in 87% (56). With 
alternate balloon inflations supported by retroperfusion, the 
incidence of angina was reduced by 50% and the time to 
onset was prolonged. In one patient with abrupt coronary 
closure, angina, hypotension and heart block were reversed 
by institution of synchronized retroperfusion until emer-
gency bypass surgery could be performed (56). Similarly, in 
a trial by the same group (57) of 164 patients undergoing left 
anterior descending angioplasty with crossover randomiza-
tion to control or retroperfusion, the time to onset of angina 
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Figure 2. Retroperfusion catheter positioned into the coronary sinus 
and great cardiac vein during coronary angioplasty of a mid left 
anterior descending stenosis. During retroperfusion, the patient 
remained asymptomatic despite prolonged balloon inflations. 
was prolonged, the frequency of angina was reduced, the 
magnitude of ST segment changes was decreased and tran-
sient regional wall motion abnormalities were ameliorated 
with coronary sinus perfusion. In the five patients in whom 
abrupt closure developed, the condition was stabilized by 
retroperfusion, without subsequent infarction. Complica-
tions were infrequent and included coronary sinus staining in 
four patients, atrial fibrillation in three and hematoma at 
internal jugular puncture sites in eight (57,58). 
Advantages and limitations compared with anterograde 
coronary perfusion. Retrograde coronary sinus perfusion 
offers some advantages over passive or active anterograde 
coronary perfusion. First, retroperfusion can maintain cir-
culation to side branches otherwise compromised by coro-
nary stenoses or angioplasty balloon inflations. Second, 
coronary sinus retroperfusion does not require special an-
gioplasty catheters or perfusates. Third, this technique does 
not require recrossing an abruptly closed segment, which 
may not be technically feasible. Despite these potential 
advantages, retroperfusion has been applied primarily in 
patients with coronary angioplasty of the left anterior de-
scending artery, the distribution of which is drained by the 
great cardiac vein. The right coronary and, to a lesser extent, 
left circumflex arteries usually drain directly into the right 
atrium, right ventricle or a portion of the coronary sinus 
which would not be perfused by a coronary sinus catheter 
advanced into the great cardiac vein. Thus, it is unclear how 
well retroperfusion protects against ischemia during angio-
plasty of the circumflex or right coronary arteries. 
Additionally, the retroperfusion technique apparently 
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provides only a moderate degree of myocardial protection 
during angioplasty; many patients still experience chest pain 
and have significant ECG changes and transient regional wall 
motion abnormalities during retroperfusion-supported bal-
loon inflations. Finally, although the average time to suc-
cessful coronary sinus cannulation is only 3 to 5 minutes by 
practiced interventionalists, overall setup time generally 
exceeds 15 minutes and inability to cannulate the coronary 
sinus precludes the use of retroperfusion in 10% to 15% of 
patients (56,58). Thus, the extent to which synchronized 
coronary sinus retroperfusion will be useful for angioplasty 
support is not defined. 
Cardiopulmonary Support 
Despite the efficacy of the previously described mechan-
ical support devices in reducing myocardial oxygen demand 
and maintaining coronary perfusion during high risk coro-
nary angioplasty, none provides total circulatory support in 
the event of catastrophic perturbations in rhythm or cardiac 
output. Until recently, total circulatory support was possible 
only with traditional cardiopulmonary bypass requiring di-
rect right atrial and central aortic cannulation or surgical 
peripheral vessel cutdown. With the development of thin-
walled, large-bore intravascular catheters, percutaneous ini-
tiation of cardiopulmonary support has become possible 
(59). Initial favorable results with percutaneous cardiopul-
monary support have been achieved in patients with cardio-
genic shock, refractory rhythm disturbances and cardiac 
arrest (24,59-62). 
Percutaneous initiation of cardiopulmonary support. The 
percutaneous technique for the currently available cardio-
pulmonary bypass device has recently been described by 
Shawl et al. (62). Briefly, after ileofemoral angiography to 
exclude significant atherosclerotic disease, the femoral ar-
tery and vein are progressively dilated to allow passage of an 
l8F or 20F sheath; the long venous cannula is advanced 
under fluoroscopy to the inferior vena cava-right atrial 
junction. After administration of 300 U/kg of intravenous 
heparin, the cannulas are attached to a portable cardiopul-
monary support system (C.R. Bard), which consists of a 
vortex-centrifugal Biomedicus pump in series with a mem-
brane oxygenator. Venous blood is aspirated from the right 
atrium and returned via the membrane oxygenator to the 
systemic circulation through the femoral artery cannula. 
Using this method, flow rates of 1 to 6 liters/min can be 
achieved. Because of reductions in preload and systemic 
vascular resistance with initiation of bypass, fluid adminis-
tration is required in most patients to maintain systemic 
arterial pressure. After bypass is discontinued, cannulas are 
removed using an external groin clamp for 4 to 8 hours; 
primary vascular surgical repair, initially used at many 
centers, has been found in most cases to have no advantage 
over the simpler percutaneous technique. 
Experience during angioplasty: the national registry. An 
initial favorable experience with cardiopulmonary support in 
776 LINCOFF ET AL. 
SUPPORT DEVICES FOR CORONARY ANGIOPLASTY 
patients undergoing high-risk coronary angioplasty (63-65), 
unprotected left main angioplasty (66) and atherectomy (67) 
prompted formation of a national registry of 14 centers 
performing angioplasty under prophylactic cardiopulmonary 
support (68). During the first 2 years of the registry, 363 high 
risk patients underwent elective supported coronary angio-
plasty (69). This series included patients with a left ventric-
ular ejection fraction of <20% (21% of patients) left main 
coronary stenosis (15%) and dilatation of the only patent 
coronary vessel (19%). Despite the high risk patient group 
reported, 95% of attempted vessels were successfully dilated 
with bypass support; overall hospital mortality rate was 6%. 
However, a significant proportion of complications oc-
curred, chiefly in relation to the access site: vascular com-
plications developed in 39% of patients and included cannula 
site infection (7.6%), thrombophlebitis (4.7%), hematoma 
(3.8%), required femoral artery repair (3.8%), femoral artery 
occlusion or pseudoaneurysm (3.8%) and transient femoral 
nerve injury (1.9%). Delayed coronary artery closure oc-
curred in seven patients (4.1%), of whom four died. Al-
though thrombocytopenia and hemolysis were rare, 43% of 
patients required transfusions due to blood loss during the 
procedure. 
Emergency cardiopulmonary support. In addition to elec-
tive initiation, cardiopulmonary support has also been effec-
tively used as emergency treatment after the development of 
cardiogenic shock (70) or hemodynamically significant com-
plications of coronary angioplasty (71). Shawl et al. (70) 
described 10 patients who were placed on cardiopulmonary 
bypass after the development of cardiogenic shock. In the 
eight patients who underwent successful angioplasty, all 
survived to a mean 10-month follow-up. Furthermore, in 
patients who had a sustained cardiac arrest during coronary 
angiography or angioplasty, bypass was instituted within a 
mean of 21 min; among the five of seven patients in whom 
further revascularization was attempted, 4 survived (71). 
The myocardial protective effect of cardiopulmonary 
support does not appear to be due to a significant increase in 
coronary perfusion. Chest pain or ischemic ST segment 
changes occur in <25% of patients, but echocardiographic 
and ventriculographic studies demonstrate that cardiopul-
monary bypass does not prevent regional wall motion abnor-
malities or ventricular dilatation induced by balloon inflation 
(68,72). Thus, bypass may be beneficial by virtue of the 
hemodynamic support it affords and the resultant decrease in 
cardiac work and oxygen demand. 
Limitations. Insertion of stiff, large-bore bypass cannulas 
may be difficult with atherosclerotic or tortuous vessels, and 
peripheral angioplasty is sometimes required before their 
placement. Use of a membrane oxygenator mandates high 
dose heparinization with the attendant bleeding risk. The 
presence of a skilled perfusionist is required during all 
phases of cardiopulmonary support. Further, the patient 
who is not a surgical candidate may become "bypass depen-
dent" during the procedure. 
Indications (Table 3). To date, no study has defined 
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Table 3. Suggested Indications for Prophylactic Versus Standby 
Cardiopulmonary Support During High Risk Coronary Angioplasty 
Prophylactic placement 
Dilation of only patent coronary vessel 
Hemodynamic instability during prior unsupported angioplasty attempts 
Preprocedure hemodynamic instability despite other support measures 
Unprotected left main angioplasty 
Standby support 
Severely impaired left ventricular function 
Target vessel supplying more than half of the viable myocardium 
which patients actually benefit from prophylactic institution 
of cardiopulmonary bypass during high risk angioplasty. 
Data from the Cardiopulmonary Support Registry (68) sug-
gest that some patients clearly do not benefit. These include 
those with left main coronary disease in whom bypass may 
make the angioplasty technically feasible, but in whom 
subsequent vessel closure may be catastrophic. The most 
likely patients to derive benefit are those who have demon-
strated hemodynamic instability during prior unsupported 
angioplasty attempts or who are to undergo dilatation of 
their only patent coronary vessel. In other high risk patients, 
prophylactic support may not be necessary. The concept of 
"standby supported angioplasty," in which patients are 
prepared for cardiopulmonary support by 5F arterial and 
venous cannula placement without actually being placed on 
bypass, is being investigated (68). In the event of complica-
tion, patients can be placed on full cardiopulmonary support 
within 5 to 15 min. Through 1989, of a total 455 patients with 
similar high risk characteristics, 363 were placed on bypass 
during angioplasty and 92 underwent standby support (73). 
Overall mortality in the two groups was the same (6%). Of 
patients on standby support, six required initiation of car-
diopulmonary bypass, two of whom died. Four other pa-
tients died without being placed on bypass. Further investi-
gation is under way into the use of standby supported 
angioplasty and into defining more clearly the groups that 
should be placed on bypass prophylactically. 
Other Support Devices 
Hemopump 
The Nimbus Hemopump@ is a catheter-mounted left 
ventricular assist device that withdraws blood directly from 
the ventricular cavity and propels it into the descending 
aorta (Fig. 3). Contained within a 21F flexible inflow cannula 
inserted through a cutdown in the femoral artery and passed 
retrograde across the aortic valve, a miniature Archimedes 
spiral vane screw pump in the base of the cannula rotates at 
27,000 rpm, producing nonpulsatile flow rates of up to 3.5 
liters/min. The Hemopump output is thus independent of left 
ventricular function or underlying cardiac rhythm. 
Experimental studies. An experimental study with full 
dose heparinization showed no significant hemolysis, throm-
bocytopenia, hypofibrinogenemia or thromboembolic events 
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Figure 3. Chest radiograph showing the Hemopump cannula posi-
tioned in the cavity of the left ventricle and passing across the aortic 
valve in a patient with cardiogeniC shock after acute myocardial 
infarction. 
with placement of the Hemopump for as long as 2 weeks 
(74). Furthermore, institution of Hemopump circulatory 
support before induced myocardial ischemia reduced sys-
tolic work load and increased collateral myocardial perfu-
sion in the ischemic region (75). Comparison of the hemo-
dynamic support afforded by the Hemopump with that of the 
intraaortic balloon pump in dogs with left anterior descend-
ing artery occlusions showed that the Hemopump is superior 
in maintaining aortic pressure while unloading the left ven-
tricle and reducing dyskinesia of the ischemic region (76). 
Clinical studies. In preliminary clinical studies (77-79) of 
patients with refractory cardiogenic shock after acute myo-
cardial infarction or cardiac surgery, improvements in car-
diac output, reduction in pulmonary wedge pressure and 
pressor requirements and improved survival were demon-
strated in patients in whom the support device could be 
successfully placed; placement failure by the femoral route 
occurred in 15% to 20% of patients. The Hemopump, by 
virtue of its ability to directly decompress the left ventricle, 
increase collateral coronary perfusion and maintain systemic 
circulation for up to 14 days independent of intrinsic cardiac 
rhythm or output, may be used for circulatory support 
during high risk coronary angioplasty. In a preliminary 
report (80) of five patients with markedly diminished left 
ventricular function, successful balloon dilatation of the 
single patent coronary vessel was accomplished with pro-
phylactic placement of the Hemopump before the coronary 
angioplasty. All procedures were successful despite occur-
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rence of prolonged atrioventricular block in one patient and 
ventricular tachycardia in three patients. 
Disadvantages of the current Hemopump design include 
its relatively large profile and high proportion of failed 
placements via the femoral artery. Cardiac output is limited 
to 3.5 liters/min and is dependent on adequate left ventricu-
lar filling. The distal catheter in the left ventriCular cavity 
may also induce serious ventricular arrhythmias, dislodge 
mural thrombi or prolapse into the aorta. 
Partial Left Heart Bypass 
A percutaneous partial left heart bypass system was 
recently used (81,82) for circulatory support during high risk 
angioplasty in a few patients. Using a trans septal approach, 
a 14F to 20F catheter is placed in the left atrium. Oxygenated 
blood is withdrawn and returned to the circulation through a 
14F to 20F femoral arterial cannula, and circulatory slipport 
has been employed for as long as 10 days. With this 
technique, successful angioplasty was performed in six high 
risk patients without significant complications. This system 
offers an advantage over percutaneous cardiopulmonary 
bypass in that no oxygenator is required. Transseptal place-
ment of large bore cannulas is technically more complex 
than right atrial access, however, and the experience thus far 
with the left heart bypass system is too limited to accurately 
assess the incidence of significant atrial septal defect or other 
complications. 
Perspectives 
Recent developments in support technology have made 
available a number of mechanical strategies for myocardial 
protection during high risk coronary angioplasty and for the 
stabilization of patients after abrupt closure or other peri pro-
cedural complications. While these deviCes may permit 
performance of very high risk coronary angioplasty, they 
cannot prevent the often catastrophic consequences of late 
vessel closure or restenosis after support has been discon-
tinued. In a large series of 352 consecutive abrupt vessel 
closures after coronary angioplasty (Emory University An-
gioplasty Data Base, H. V. Anderson, personal communiCa-
tion), 46% of closures occurred after the patient had left the 
catheterization laboratory. Thus, coronary artery bypass 
surgery remains the preferred procedure for situations such 
as left main stem or critical three-vessel disease, and sup-
ported angioplasty should be undertaken in such patients 
only when surgical revascularization is otherwise contrain-
dicated. Furthermore, a substantial vascular complication 
rate is associated with these techniques, especially with 
devices that require large bore arterial and venous cannula-
tion. The potential for long-term dependence after angio-
plasty should be considered before patients with severely 
impaired ventricular function are placed on total circulatory 
support systems. These issues mandate judicious selection 
778 LINCOFF ET AL. 
SUPPORT DEVICES FOR CORONARY ANGIOPLASTY 
of patients for the prophylactic or emergent use of support 
devices for coronary angioplasty. 
Selection of patients for prophylactic support. Although 
coronary angioplasty is well tolerated in most cases, me-
chanical support devices may be of prophylactic value in 
several clinical settings. Severe ongoing ischemia before 
coronary angioplasty may be initially treated by intraaortic 
balloon counterpulsation. In the absence of marked hemo-
dynamic compromise, almost all patients show dramatic 
improvement. Although anterograde or retrograde coronary 
perfusion may be useful, the value of these techniques as a 
primary means of prophylactic support in patients with 
severe ongoing ischemia has not been extensively investi-
gated. In patients with a target vessel supplying a majority of 
residual viable myocardium, balloon inflation may result in 
hemodynamic deterioration or rapid demise in the event of 
abrupt coronary closure. The "jeopardy score," an angio-
graphic estimate of the proportion of viable myocardium that 
may become akinetic after vessel closure, is a powerful 
predictor of in-hospital death (83). With a substantial portion 
of myocardium at risk, more aggressive circulatory support, 
such as percutaneous bypass, may be considered. 
In patients undergoing angioplasty of their only patent 
coronary vessel, particularly in those with markedly dimin-
ished left ventricular function (ejection fraction <20%), 
prophylactic institution of cardiopulmonary support is prob-
ably indicated. For less severely compromised patients, a 
growing body of evidence indicates that an adequate margin 
of safety is provided by standby rather than full prophylactic 
cardiopulmonary bypass. Because neither the intraaortic 
balloon pump nor cardiopulmonary support clearly improves 
myocardial oxygen supply, the addition of a perfusion tech-
nique to hemodynamic support may prove beneficial. 
Selection of patients in complicated coronary angioplasty. 
If suboptimal angiographic results are achieved by standard 
coronary angioplasty, prolonged balloon inflation may be 
used to "tack down" dissection flaps and improve the 
immediate angiographic outcome. Crossover trials show 
benefit of both anterograde and retrograde coronary perfu-
sion techniques in allowing prolonged balloon inflations with 
less chest pain or myocardial dysfunction. The choice of 
perfusion method depends on factors such as coronary 
anatomy, lesion morphology and institutional experience. 
The autoperfusion balloon catheter is clearly the simplest 
device to use and is adequate in most cases. If coronary or 
lesion anatomy is unsuitable for passage of the relatively 
large and stiff autoperfusion catheter or if systemic blood 
pressure is inadequate to assure adequate passive perfusion, 
an anterograde or retrograde pumping technique should be 
used. Anterograde transcatheter infusion of autologous 
blood or fluosol does not require specialized equipment or 
additional vascular access, but may be limited by side branch 
ischemia or insufficient flow rates to large coronary beds. 
The coronary sinus retroperfusion system can provide 
higher coronary blood flow rates, but has demonstrated 
efficacy only in the left anterior descending artery distribu-
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tion and requires a complex pumping system and placement 
of additional sheaths in the femoral artery and internal 
jugular vein. 
Therapy after abrupt vessel closure. With abrupt closure 
during coronary angioplasty, initial therapy is aimed at 
restoring coronary perfusion and hemodynamic stabiliza-
tion. Although use of prolonged balloon inflations, endolu-
menal stents, and laser balloon angioplasty may serve to 
reestablish coronary patency, if the closure persists despite 
these efforts, therapy should be directed toward ameliora-
tion of ischemia. If myocardial ischemia is relieved before 
coronary bypass surgery, a more favorable operative out-
come may be expected (84). To this end, a coronary perfu-
sion catheter may be placed to restore distal myocardial 
blood flow; insertion of an intra-aortic balloon pump may 
also be required. If aggressive circulatory support is indi-
cated due to severe left ventricular dysfunction and hemo-
dynamic collapse, percutaneous cardiopulmonary bypass or 
Hemopump placement may be needed. Catastrophic acute 
right ventricular failure may occur as a result of proximal 
right coronary artery occlusion during angioplasty; this 
represents an extremely difficult management problem. Al-
though surgical insertion of balloon counterpulsation devices 
into the pulmonary artery has been reported (85), long-term 
percutaneous support techniques have not been used for 
right ventricular failure. 
In this relatively early stage of support technology, there 
have already been steps to improve safety of high risk 
coronary angioplasty and allow its application to those who 
may have otherwise been excluded from percutaneous re-
vascularization; extensive refinements can be anticipated. 
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